Rationale: Fetuses that develop in diabetic mothers have a higher incidence of birth defects that include cardiovascular defects, but the signaling pathways that mediate these developmental effects are poorly understood. It is reasonable to hypothesize that diabetic maternal effects are mediated by 1 or more pathways activated downstream of aberrant glucose metabolism, because poorly controlled maternal glucose levels correlate with the frequency and severity of the defects.
R eceptor-mediated signaling is required for endothelial cell proliferation and migration, processes that are critical to blood vessel formation and function. 1 Signaling downstream of receptor engagement in endothelial cells leads to the activation of several pathways, including phospholipase C-␥ activation, to produce diacylglycerol (DAG). DAG in turn activates downstream targets to affect endothelial cell behaviors. Signals that are upregulated in diabetes, such as vascular endothelial growth factor-A (VEGF-A) and endothelin-1 (ET1), generate DAG. DAG is also produced by aberrant glucose metabolism, and DAG levels are elevated in diabetic animals and patients. 2, 3 Diabetic individuals have compromised angiogenesis and blood vessel function, and fetuses of diabetic mothers have an increased incidence of birth defects, including vascular defects. 3, 4 It is assumed that these vascular defects are mediated, at least in part, by elevated DAG levels, because mouse embryos recovered from diabetic mothers had elevated DAG levels and increased developmental defects 3 ; however, it is not fully understood how elevated DAG leads to vessel dysfunction.
The effects of DAG on cell signaling are mimicked by phorbol esters, tumor promoters that also affect endothelial proliferation, cellular morphology, apoptosis, and barrier function. [5] [6] [7] [8] [9] DAG and phorbol esters are potent activators of the protein kinase C (PKC) family of proteins. Numerous mammalian PKC isoforms fall into several subfamilies, and DAG/ phorbol esters activate PKC signaling by binding to C1 domains found in the classic (␣, ␤, ␥) and novel (␦, ⑀, , ) subgroups of PKCs. 10 Recently, several non-PKC protein families were identified that contain C1 domains and respond to DAG and phorbol esters, which suggests that some DAG/phorbol ester-mediated responses require these proteins. 11 Ras guanyl-releasing proteins (RasGRPs) are non-PKC DAG/phorbol ester receptors that function as guanine nucleotide exchange factors and activate the Ras family of GT-Pases. 12, 13 Ras proteins are localized to membranes, and their activation is controlled in part by proximity to guanine nucleotide exchange factors, such that recruitment of guanine nucleotide exchange factors to membranes can activate Ras. Both DAG and phorbol esters recruit RasGRPs to membranes via the C1 domain. Active Ras in turn activates several effector pathways such as MEK/ERK, p38 mitogen-activated protein kinase (p38 MAPK), and JNK. Ras proteins are activated by phorbol esters in cultured endothelial cells, 14 and PKCs also contribute to Ras and ERK activation in response to phorbol esters in endothelial cells; however, the potential role of non-PKC DAG/phorbol ester receptors in this response has not been investigated.
The RasGRP family of non-PKC phorbol ester receptors has 4 family members. The RasGRPs have limited sites of expression in vivo, and genetic deletion experiments reveal a nonredundant function for the RasGRPs in hematopoietic and endothelial cells. RasGRP1 transduces signals downstream of the T-cell receptor for T-cell maturation, and both RasGRP1 and RasGRP3 affect B-cell function in complex ways. [15] [16] [17] RasGRP2 recently was reported to have effects on vascular development in Xenopus. 18 We identified RasGRP3 in a murine-based gene-trap screen as a locus expressed in endothelial cells of developing vessels and required for mediation of the endothelial cell effects of DAG/phorbol esters. 19 The expression profile and DAG/phorbol ester interactions suggested that RasGRP3 might mediate the effects of excess DAG on developing vessels in diabetes.
RasGRP3 activates Ras, Rap, and R-ras in vitro and in mouse embryo fibroblasts. 20 In addition to requiring DAG/ phorbol ester activity for membrane localization, 21 RasGRP3 is phosphorylated by PKC at Thr133, and this phosphoryla-tion is required for RasGRP3 activity in B cells. 22, 23 Ras-GRP3 also binds dynein light chain, a component of a microtubule minus-end-directed motor, but the significance of this binding in vivo is not clear. 24 We showed that RasGRP3 is expressed in angiogenic vessels. Although a genetic loss of function generated by the gene trap did not affect development, embryonic vessels exposed to phorbol ester exhibited dysmorphogenesis that required Rasgrp3 function, thus identifying RasGRP3 as a novel endothelial phorbol ester receptor. 19 Here, we further characterize the role of RasGRP3-mediated Ras signaling in embryos, endothelial cells, and developing vessels. We find that loss of Rasgrp3 function significantly reduces diabetes-induced birth defects in vivo, including embryonic vascular defects. We show that Ras is a target of RasGRP3 in endothelial cells and that RasGRP3 is required for ET1-mediated effects on vessel morphogenesis. Our data are consistent with a model in which RasGRP3 signaling in embryonic endothelial cells transduces signals downstream of DAG that affect endothelial cell behaviors and lead to vessel dysmorphogenesis. Thus, excess DAG in diabetes likely overactivates RasGRP3, and this contributes to the perturbed development of fetuses in diabetic environments.
Methods

Diabetic Mice and Embryo Analysis
Female mice (C57Bl/6J purchased from The Jackson Laboratory, Bar Harbor, ME, or Rasgrp3 gt/gt (a loss-of-function null mutation 19 backcrossed to N8 on the C57Bl/6J background) at 6 to 8 weeks of age were made diabetic according to the protocol in the Animal Models of Diabetic Complications Consortium. Alternatively, Ins2 Akita /ϩ mice on the C57Bl6/J background (The Jackson Laboratory, #003548) were bred to obtain Ins2 Akita ;Rasgrp3 gt/gt mice. Blood glucose was monitored weekly, and mice with blood glucose levels Ͼ250 mg/dL were considered diabetic. Mice were mated to genotype-matched males, and embryos were harvested at embryonic day 9.5 (E9.5), fixed, and whole-mount stained for platelet endothelial cell adhesion molecule as described previously. 25 Stained embryos were imaged and scored for defects as described in the Online Data Supplement (available at http://circres.ahajournals.org).
Whole-embryo culture was performed on embryos dissected at E7.5 or E8.5, in roller bottles as described previously. 26 Some embryos were treated with PMA (phorbol 12-myristate 13-acetate) 50 nmol/L and some with glucose 20 mmol/L during the culture period. After 24 hours, embryos were removed and photographed.
Endothelial Cells
Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics (San Diego, CA), cultured according to the manufacturer's protocol, and used between passages 2 and 8. Transfections were performed with an Amaxa Nucleofector (Lonza, Basel, Switzerland) according to directions. For staining, cells were fixed, permeabilized, blocked, and incubated with Alexa Fluor 555phalloidin (Molecular Probes, Carlsbad, CA). Migration assays were performed 48 hours after transfection as described in the supplemental Methods. Average velocity and distance to origin of cells were calculated with trajectory measures as diagrammed in Figure 3J .
Mouse endothelial cells (wild type and Rasgrp3 gt/gt ) were generated and expanded as described previously, 27, 28 with minor modifications. Proliferation assays and migration assays were as described in the Online Data Supplement.
Embryonic Stem Cell Differentiation and Analysis
Wild-type (WT; ϩ/ϩ ) and RasGRP3-deficient (Rasgrp3 gt/gt ) embryonic stem (ES) cells were maintained and differentiated for 8 days as described previously. 29 were pretreated with the appropriate inhibitor for 2 hours before addition of PMA 100 nmol/L for 24 hours. For ET1 stimulation, ET1 100 nmol/L in fresh medium was added daily between days 5 and 8. Antibody staining of ES cell cultures was as described previously. 25, 29 Quantitative image analysis of platelet endothelial cell adhesion molecule-stained ES cell cultures was performed as described previously. 25
Ras and ERK Activation Assays
HUVECs (50% to 80% transfected by green fluorescent protein labeling after transfection) or mouse endothelial cells were grown to near confluence for 48 hours, serum-starved overnight, then processed as described in the supplemental Methods for Ras-GTP immunoprecipitation or total Ras, phosphorylated ERK, or total ERK Western blots.
Results
Loss of Rasgrp3 Protects Embryos From Diabetes-Induced Birth Defects
Because RasGRP3 is expressed in developing vessels and somites of midgestation mouse embryos, 19 we reasoned that embryos exposed to elevated DAG signaling would be susceptible to effects of RasGRP3-mediated signaling in vivo. Therefore, we examined the effects of elevated DAG/phorbol ester, glucose, and the diabetic environment on these stages of mouse development. We first mimicked elevated DAG signaling by incubating mouse embryos harvested at E7.5 for 24 hours in phorbol ester under whole-embryo culture conditions (Online Figure I ). WT embryos exposed to PMA were severely affected (Online Figure I , A-D), with loss of anterior-posterior landmarks and yolk sacs with large cavities. In contrast, Rasgrp3 gt/gt mutant embryos incubated under the same conditions were surprisingly intact, and anterior-posterior landmarks were evident, along with intact yolk sacs (Online Figure I , E-H). We next incubated embryos in glucose 20 mmol/L for 24 hours to mimic the diabetic environment (Online Figure II) . Glucose exposure between E8.5 and E9.5 led to vascular defects in WT embryos, and likely nonvascular defects such as perturbed somitogenesis and axis defects as well. In contrast, Rasgrp3 gt/gt mutant embryos were relatively refractory to the teratogenic effects of elevated glucose. To more precisely define the effects of a diabetic environment on developing embryos, we induced diabetes in female mice, then set up matings and examined embryos. On an outbred background, WT embryos often showed quite severe defects, including aberrant somite formation and vessel patterning, rela- ; and lane 6, Ins2 Akita ;Rasgrp3 gt/gt diabetic (nϭ19). **PՅ0.001 for WT versus WT-STZ diabetic; ***PՅ0.00001 for WT versus Ins2 Akita ; ##PՅ0.0001 for Ins2 Akita ;Rasgrp3 ϩ/ϩ versus Ins2 Akita ;Rasgrp3 gt/gt . tive to Rasgrp3 gt/gt mutant embryos (Online Figure III) . To make more rigorous comparisons, we next examined embryos on the C57Bl6/J inbred background. We induced diabetes chemically via streptozotocin (STZ), and we also used mice carrying the Ins2 Akita mutation that induces diabetes genetically. We monitored the average maternal blood glucose at the time of euthanasia via tail bleed and found the following values: WT STZ, 381 mg/dL; Rasgrp3 gt/gt STZ, 448 mg/dL; Ins2 Akita ;Rasgrp3 gt/gt , 387 mg/dL. Embryos were harvested from diabetic mothers at E9.5 and whole-mount stained for platelet endothelial cell adhesion molecule to visualize vessel development and patterning, and the severity of defects in head plexus vessels, intersomitic vessels, and trunk/somite was scored as described in Methods (Figure 1 ). WT embryos from mothers with diabetes that was induced either chemically or genetically had a significantly elevated developmental severity index compared with controls ( Figures 1A, 1B , 1E, and 1O; Online Figure IV ). Closer examination of the somite region showed defects in somites and in the pattern of intersomitic vessels ( Figures 1G through 1J) , and similar defects were seen in the vascular plexus of the head (Figures 1 K through 1N ). In contrast, embryos similarly developing in diabetic mothers but genetically deficient for Rasgrp3 appeared relatively unaffected, and their developmental severity index was significantly lower than WT counterparts and close to control levels (Figures 1C through 1O; Online Figure  IV ). Analysis of yolk sacs from these embryos showed a low level of vascular defects that did not significantly correlate with genotype, diabetic condition, or the severity of the corresponding embryo (Online Figure V and 
Ras Is a Target of RasGRP3 in Endothelial Cells
To explore how RasGRP3 signaling contributes to diabetesinduced developmental defects, we first analyzed signaling in HUVECs that upregulated RasGRP3 activity, because the developmental defects are predicted to result from overactivation of RasGRP3 by DAG ( Figure 2 ). WT RasGRP3 linked to a green fluorescent protein reporter and constructs in which a K-Ras CAAX or H-Ras CAAX sequence was linked to the protein were transiently expressed in HUVECs (Figure 2A ). The CAAX sequences localize RasGRP3 to membranes, 20 which mimics DAG-promoted activation to place the activator in physical proximity to Ras. Thus, these constructs are predicted to be "constitutively active" in terms of their action on Ras and provide gain-of-function activity independent of any overexpression effects. Overexpression of WT RasGRP3 did not significantly increase Ras activation over baseline, but both of the CAAX-tagged RasGRP3 proteins stimulated significant Ras activation ( Figures 2B and 2C ). ERK activation is downstream of Ras activation, and in HUVECs, both CAAX-tagged RasGRP3 proteins also significantly induced ERK activation ( Figures 2B and 2C) . These data indicate that Ras is a target of RasGRP3 in endothelial cells.
To examine the cellular responses of endothelial cells to RasGRP3-mediated signaling, we examined the effects of RasGRP3 overactivation on the cytoskeleton, because in other cell types, Ras activation affects the cytoskeleton. 30, 31 HUVECs that expressed the constructs described above were stained for microtubules (␣-tubulin, data not shown) and actin (phalloidin; Figures 3A through 3H) . The microtubule staining pattern was not affected by overexpression of RasGRP3 (data not shown); however, the actin cytoskeleton was dramatically altered in endothelial cells that overexpressed membrane-localized RasGRP3 (Figures 3E through 3H ). RasGRP3-CAAX-expressing cells appeared larger and flatter, and they had very few actin stress fibers. Cortical actin was also diminished in endothelial cells that overexpressed RasGRP3-CAAX. Because actin stress fibers are implicated in proper migration, we investigated the migratory behavior of endothelial cells that overexpressed RasGRP3 (Figures 3I  through 3L ). Endothelial cells that overexpressed RasGRP3 were identified by green fluorescent protein expression, and all cells were labeled with cell tracker ( Figure 3I ). Cells were imaged, and the average velocity and distance migrated from origin were calculated as described in Methods ( Figure 3J ). None of the RasGRP3 proteins affected the overall velocity of the cells, but the CAAX-tagged RasGRP3 proteins both significantly inhibited the distance migrated from the origin (Figures 3K and 3L) . These results show that endothelial cells that overexpress membrane-localized (and thus activated) RasGRP3 have a perturbed actin cytoskeleton and an attenuated ability to migrate in a forward direction.
To investigate the effects of loss of function for Rasgrp3 on signaling pathway(s), endothelial cells were isolated and immortalized from WT and Rasgrp3 gt/gt mice. The cells were expanded clonally, and the endothelial identity of the cells was verified by expression of endothelial markers. The cell lines were more than 95% positive for platelet endothelial cell adhesion molecule, vascular endothelial cadherin, and intercellular adhesion molecule-2 (Online Figure VI , A-D, and data not shown). RT-PCR analysis showed loss of RasGRP3 expression in Rasgrp3 gt/gt endothelial cells, and growth curves showed that WT and Rasgrp3 gt/gt endothelial cells grew at similar rates (Online Figure VI , E-F).
We investigated whether RasGRP3 was necessary for Ras and ERK activation downstream of DAG/phorbol ester stimulation. WT and Rasgrp3 gt/gt endothelial cells incubated with PMA were evaluated for changes in the levels of Ras and ERK activation. WT endothelial cells stimulated with PMA had elevated levels of active Ras and active ERK. In contrast, Rasgrp3 gt/gt endothelial cells stimulated with PMA showed no detectable Ras activation, and ERK activation was attenuated ( Figure 4A ; Online Figure X, A) . These results reveal a requirement for RasGRP3 in Ras/ERK signaling downstream of DAG/phorbol ester stimulation in endothelial cells.
We next examined the signaling requirements downstream of RasGRP3 activation in endothelial cells of developing vessels using a mouse ES cell-differentiation model that supports the formation of primitive blood vessels in vitro via a programmed differentiation. 29, 32, 33 We previously showed that ES cell-derived blood vessels respond to phorbol ester stimulation with a dramatic vessel dysmorphogenesis that is dependent on Rasgrp3 function 19 (Online Figure VII, A-D) . We therefore investigated whether signaling downstream of activated RasGRP3 in developing vessels used the Ras effector pathways MEK/ERK, p38 MAPK, or JNK. The vessel dysmorphogenesis seen on PMA stimulation was In contrast, the p38 MAPK inhibitor SB203580 had no effect on PMA-induced vessel dysmorphogenesis (Online Figure VII , G-I), and the JNK inhibitor SP600125 showed a similar lack of effect (data not shown). Thus, RasGRP3-dependent DAG/phorbol ester signaling in developing vessels requires MEK but not p38 MAPK or JNK downstream of Ras GTPases.
Activation of RasGRP3 in B cells requires, in addition to membrane localization, phosphorylation by PKC. To test PKC function in endothelial cells, we exposed ES-derived vessels to PKC inhibitors concomitant with exposure to phorbol ester (Online Figure VIII 
RasGRP3 Is Required for ET1-Mediated Ras and ERK Signaling in Endothelial Cells
Although phorbol ester mimics endogenous DAG production and signaling downstream of physiological inputs, it does not identify the physiological signals that normally activate RasGRP3-dependent signaling in endothelial cells. To identify physiologically relevant signals upstream of RasGRP3 in endothelial cells, we investigated signaling mediated by VEGF-A and ET1, 2 angiogenic factors that use DAG-Ras-ERK downstream signaling. WT and Rasgrp3 gt/gt endothelial cells were stimulated with VEGF or ET1, and levels of active Ras and ERK were analyzed ( Figures 4B and 4C; Online Figure X, B) . As predicted, WT endothelial cells had increased levels of active Ras and ERK on treatment with either VEGF or ET1. In contrast, although Rasgrp3 gt/gt endothelial cells had elevated levels of active Ras and ERK with VEGF treatment, they showed no increase in active Ras and attenuated active ERK with ET1 stimulation. Thus, RasGRP3 is required for Ras and ERK activation downstream of ET1 stimulation in endothelial cells. These results identify ET1 as a physiological signal for RasGRP3-mediated signaling in endothelial cells.
RasGRP3 Is Required for ET1-Induced Stimulation of Endothelial Cell Proliferation and Migration
Activation of Ras-ERK signaling by ET1 stimulates endothelial cell proliferation and migration. 34 To determine whether ET1-induced endothelial cell proliferation and migration were RasGRP3-dependent, WT and Rasgrp3 gt/gt endothelial cells were treated with ET1 and evaluated. WT endothelial cells exhibited more than a 2-fold increase in mitotic index over baseline with ET1 treatment, whereas Rasgrp3 gt/gt endothelial cells did not exhibit a significant change in their mitotic index with ET1 treatment (Figures 5A through 5E) . In a Boyden chamber migration assay, VEGF induced migration of both WT and Rasgrp3 gt/gt endothelial cells significantly and to a similar degree; however, ET1 only stimulated migration of WT endothelial cells and did not significantly induce migration of Rasgrp3 gt/gt endothelial cells ( Figure 5F ). These results indicate that ET1-induced proliferation and migration require Rasgrp3 function, whereas VEGF-induced migration occurs independent of RasGRP3.
RasGRP3 Mediates Vessel Dysmorphogenesis Induced by ET1
Because both ET1-induced endothelial cell proliferation and migration are RasGRP3-dependent, we investigated whether ES cell-derived blood vessels had RasGRP3-dependent dysmorphogenesis induced by ET1 ( Figure 6 ). ET1 treatment of WT vessels led to loss of the fine vascular network and significantly increased vascular area (Figures 6A, 6B, and 6E ). This response was Rasgrp3-dependent, because Rasgrp3 gt/gt vessels retained the fine vascular network and did not exhibit increased vascular area with ET1 treatment (Figures 6C through 6E ). ET1-mediated vessel dysmorphogenesis was also dependent on PKC activity, because PKC inhibition blocked ET1 effects on vessels (Online Figure IX) . Thus, developing vessels exhibited vessel dysmorphogenesis in response to ET1, and that response required RasGRP3 and PKC function. Taken together, these data suggest 
. RasGRP3 is required for Ras-ERK activation downstream of phorbol ester and ET1 but not VEGF-A. A, WT and
Rasgrp3 gt/gt endothelial cells were treated with PMA and processed for Ras and ERK activation. Compared with WT endothelial cells, Rasgrp3 gt/gt endothelial cells did not show increased activated Ras (Ras-GTP) and had an attenuated activation of phosphorylated ERK (pERK). B, WT and Rasgrp3 gt/gt endothelial cells were treated with ET1 or VEGF-A and processed for Ras activation. WT endothelial cells had increased levels of activated Ras (Ras-GTP) in response to both VEGF and ET1, whereas Rasgrp3 gt/gt endothelial cells had increased activated Ras (Ras-GTP) in response to VEGF-A but an attenuated response to ET1. C, WT and Rasgrp3 gt/gt endothelial cells were stimulated with ET1 or VEGF-A and processed for ERK activation. WT endothelial cells had increased levels of pERK in response to both VEGF and ET1, whereas Rasgrp3 gt/gt endothelial cells had increased pERK in response to VEGF-A but attenuated in response to ET1. Experiments are representative of at least 3 replicates.
that RasGRP3 is required for ET1-induced endothelial cell angiogenic responses.
Discussion
RasGRP3 is an activator of Ras family GTPases that is expressed in angiogenic vessels and is required for the DAG/ phorbol ester-mediated responses of these vessels. Here, we posited that RasGRP3 is overactivated in embryos that develop in a diabetic environment and are susceptible to birth defects, and we showed that loss of RasGRP3 significantly attenuated the detrimental effects of a diabetic environment on embryonic vascular development. We also defined the molecular and cellular processes perturbed by DAG/phorbol ester-induced activation of RasGRP3 activation in endothelial cells of developing vessels. We defined ET1 as an upstream input and Ras as a target of RasGRP3 in endothelial cells, and we showed that manipulation of RasGRP3 perturbs endothelial migration. These data led to a model of RasGRP3-mediated signaling in endothelial cells that includes a molecular mechanism, cellular phenotype, and effects on the developing embryo in a diabetic environment (Figure 7) .
We activated RasGRP3 in developing vessels using phorbol ester as a DAG mimic, and RasGRP3-dependent vessel dysmorphogenesis required MEK/ERK signaling. The present data indicate that Ras is a primary target of RasGRP3 in endothelial cells, because overexpression of RasGRP3 linked to either K-Ras CAAX or H-Ras CAAX domains significantly activated both Ras and ERK, whereas loss-of-function analysis showed that RasGRP3 was required for ET1-or DAG/phorbol ester-mediated Ras and MEK/ERK activation. The present data do not rule out that RasGRP3 activates other Ras GTPases in endothelial cells, but they suggest that signaling through Ras to MEK/ERK is critical for the vascular response to DAG. RasGRP3 is normally activated by A, B) or Rasgrp3 gt/gt (C, D) endothelial cells were stained for platelet endothelial cell adhesion molecule (PECAM; green) and PH3 (red). E, Representative areas were imaged and mitotic cells counted. The relative mitotic index was increased significantly in WT endothelial cells treated with ET1 but not in Rasgrp3 gt/gt endothelial cells treated with ET1. **PՅ0.001 relative to WT untreated; ###PՅ0.001 relative to ET1-treated WT endothelial cells. F, Transwell migration assays. WT endothelial cells had significantly increased migration toward both ET1 and VEGF-A compared with control, whereas Rasgrp3 gt/gt endothelial cells had significantly increased migration toward VEGF-A but not toward ET1. *PՅ0.01 relative to untreated; **PՅ0.0001 relative to untreated; ##PՅ0.0001, Rasgrp3 gt/gt ET1-treated versus WT ET1-treated. ET1 (B, D) , then fixed and stained for platelet endothelial cell adhesion molecule (green) on day 8. E, Representative images were quantified for vascular area. WT vessels treated with ET1 had significantly increased vascular area, whereas ET1-treated Rasgrp3 gt/gt vessels did not have increased vascular area. **PՅ0.01 relative to control.
both localization to membranes via DAG binding to its C1 domain and PKC phosphorylation. 12 Overexpression of Ras-GRP3 alone was not sufficient to activate endothelial Ras, but overexpression of membrane-localized forms was sufficient for activation, which suggests that endogenous PKC levels are not rate-limiting for RasGRP3 activation in endothelial cells. The present studies also revealed a requirement for classic/novel PKC isoform activity in the response of developing vessels to DAG/phorbol esters and ET1. Although it is possible that the PKC requirement is downstream of the genetic requirement for RasGRP3, we favor the hypothesis that PKC phosphorylation of RasGRP3 is required for its activity in endothelial cells, as has been shown in B cells. 22, 23 Elevated RasGRP3 activity affects specific cellular responses of endothelial cells. Endothelial cells that overexpress activated RasGRP3 are flattened relative to controls, a phenotype also observed in neural cells that express activated RasGRP3. 20 Consistent with this phenotype, the actin cytoskeleton is perturbed in these cells, with loss of stress fibers and reduction of the cortical actin ring. The perturbation of the actin cytoskeleton in endothelial cells that overexpress RasGRP3 is similar to actin perturbations seen in tumor cells that express activated Ras. [35] [36] [37] In general, Ras activation reduces actin stress fiber formation, primarily through effects on RhoA activity but also via MEK signaling to ERK1/2 and ERK5. 30, 31, 38 Actin stress fibers link to focal adhesions on the ventral side of cells, and this linkage promotes actomyosin contractility. 39, 40 In terms of migration, stress fibers are thought to act as rudders that keep cells migrating directionally. 41, 42 Consistent with this idea, we find that endothelial cells that overexpress activated RasGRP3 have normal velocity but significantly reduced migration relative to the origin over time. This finding suggests that the cells can move, but their ability to link one movement to the next in a coordinated fashion is impaired. Thus, overexpression of activated Ras-GRP3 mimics Ras overactivation and prevents orderly forward migration of endothelial cells.
Complementary loss-of-function analysis showed that Ras-grp3 function is required for DAG/phorbol ester-mediated Ras activation, as is predicted to occur in diabetic environments with elevated DAG levels. Interestingly, RasGRP3 is involved in Ras/ERK signaling downstream of ET1 in endothelial cells. ET1 is elevated in diabetic milieus 43 and leads to DAG production, so perhaps 2 sources of DAG (DAG produced via elevated glucose and DAG produced via elevated ET1 signaling) contribute to RasGRP3-mediated vascular pathologies in diabetic animals. In contrast, a second signal that is elevated in diabetic environments, VEGF-A, does not appear to require RasGRP3 for Ras-mediated signaling, although RasGRP3 expression is upregulated by VEGF-A. 19 Several studies reported that ET1 angiogenic effects required VEGF-A. 44, 45 In light of our work, it is possible that this VEGF-A requirement reflects a need for VEGF-A-stimulated RasGRP3 expression. Thus, the requirement for RasGRP3 in ET1-mediated signaling may link the activities of the 2 pathways in diabetes.
Because diabetes is accompanied by elevated DAG levels and leads to developmental defects, including vascular defects, we hypothesized that in a diabetic fetal environment, elevated maternal glucose crosses the placenta, where it is metabolized to DAG. The excess DAG ectopically activates embryonic RasGRP3, and downstream activation of Ras signaling contributes to the increased incidence of developmental problems. This hypothesis predicts that embryos that lack Rasgrp3 will be less susceptible to diabetes-induced birth defects, and in fact, in the present study, embryos that lacked Rasgrp3 were significantly protected from developmental defects produced in a diabetic fetal environment. This was true whether the mothers were diabetic as a result of STZ destruction of pancreatic ␤-cells or via the Ins2 Akita mutation, which inactivates the insulin II gene and thus leads to diabetes. 46 The embryonic defects we documented were similar to the defects reported by others. 3, 4 Interestingly, embryos that lacked Rasgp3 function and developed in diabetic mothers had significantly fewer defects in develop- ing somites and developing vessels, 2 embryonic organs that express RasGRP3. 19 The vascular defects seen in WT embryos from diabetic mothers were consistent with the endothelial migration defects observed in primary endothelial cells, because the intersomitic vessels were sometimes blunted, with expanded migratory fronts. Interestingly, although yolk sac vessels showed some pattern defects, these did not correlate significantly with embryo genotype, diabetic environment, or overall embryo defects, in contrast to another group who described significant diabetes-induced yolk sac vasculopathy. 4, 47 This indicates that the observed diabetesinduced embryonic defects were not secondary to yolk sac defects that compromised overall embryonic health.
Was the protection afforded by loss of RasGRP3 from the maternal compartment, the embryonic compartment, or both? Several lines of evidence support a critical role for embryonic Rasgrp3 function in mediating the effects of diabetes. First, another study showed that DAG levels and activated PKC are elevated in embryos from diabetic mothers, 3 which indicates that upstream requirements for RasGRP3 activation are in place in the embryo. In the present study, mothers that lacked RasGRP3 became diabetic, and their average blood glucose at the time of euthanasia was higher than WT controls. Wholeembryo culture with medium supplemented with PMA showed that embryos that lacked Rasgrp3 were significantly protected from the severe PMA-induced perturbations seen in WT embryos. Finally, embryos exposed to elevated glucose had increased defects that were RasGRP3-dependent, which shows that the RasGRP3 status of the embryo is critical to its response to maternal glucose. Taken together, these findings indicate that lack of Rasgrp3 function in the embryo is critical for protection from developmental defects, and that potential maternal effects of Rasgrp3 loss do not impact the elevated glucose levels that lead to elevated DAG and diabetes.
The finding that RasGRP3 mediates the effects of a diabetic environment on embryonic development, including vascular development, suggests that RasGRP3 may be a new and useful therapeutic target for prevention of diabetes-associated birth defects. The lack of embryonic defects with Rasgrp3 loss of function under normal conditions (the present study and Roberts et al 19 ) indicates that blockade of RasGRP3 is not detrimental to overall development. The focus of the present study was analysis of gain of function and loss of function for RasGRP3 in developing vessels and endothelial cells, and we have shown that RasGRP3-mediated signaling uses Ras/ERK as a target and mediates ET1 effects on angiogenesis. It will be interesting to determine whether RasGRP3-mediated signaling is important in adult vascular pathologies.
